Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All ivermectin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19ivm.org COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 70% Improvement Relative Risk Hospitalization 67% Case 44% Ivermectin for COVID-19  Kerr et al.  Prophylaxis Is prophylaxis with ivermectin beneficial for COVID-19? PSM retrospective 159,561 patients in Brazil (Jul - Dec 2020) Lower mortality (p<0.0001) and hospitalization (p<0.0001) c19ivm.org Kerr et al., Cureus, December 2021 Favors ivermectin Favors control

Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching

Kerr et al., Cureus, doi:10.7759/cureus.21272 (date from preprint)
Dec 2021  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
 
*, now known with p < 0.00000000001 from 102 studies, recognized in 22 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments. c19ivm.org
PSM retrospective 220,517 patients in Brazil,133,051 taking ivermectin as part of a citywide prophylaxis program, showing significantly lower hospitalization and mortality with treatment.
Additional results are presented here: odysee.com, including improved efficacy with analysis based on irregular/regular use, and a strong dose-response relationship.
Confirmation from independent analysis of the raw data: twitter.com.
See Mills regarding medrxiv.org.
This is the 70th of 102 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 560 quintillion).
49 studies are RCTs, which show efficacy with p=0.00000038.
risk of death, 70.0% lower, RR 0.30, p < 0.001, treatment 25 of 3,034 (0.8%), control 79 of 3,034 (2.6%), NNT 56, adjusted per study, multivariate linear regression, propensity score matching.
risk of hospitalization, 67.0% lower, RR 0.33, p < 0.001, treatment 44 of 3,034 (1.5%), control 99 of 3,034 (3.3%), adjusted per study, multivariate linear regression, propensity score matching.
risk of case, 44.5% lower, RR 0.56, p < 0.001, treatment 4,197 of 113,845 (3.7%), control 3,034 of 45,716 (6.6%), NNT 34.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Kerr et al., 11 Dec 2021, retrospective, propensity score matching, Brazil, peer-reviewed, 9 authors, study period July 2020 - December 2020, dosage 200μg/kg days 1, 2, 16, 17, 0.2mg/kg/day for 2 days every 15 days.
This PaperIvermectinAll
Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching
Lucy Kerr, Flavio A Cadegiani, Fernando Baldi, Raysildo B Lobo, Washington Luiz O Assagra, Fernando Carlos Proença, Pierre Kory, Jennifer A Hibberd, Juan J Chamie-Quintero
Cureus, doi:10.7759/cureus.21272
Background: Ivermectin has demonstrated different mechanisms of action that potentially protect from both coronavirus disease 2019 (COVID-19) infection and COVID-19-related comorbidities. Based on the studies suggesting efficacy in prophylaxis combined with the known safety profile of ivermectin, a citywide prevention program using ivermectin for COVID-19 was implemented in Itajaí, a southern city in Brazil in the state of Santa Catarina. The objective of this study was to evaluate the impact of regular ivermectin use on subsequent COVID-19 infection and mortality rates. Materials and methods: We analyzed data from a prospective, observational study of the citywide COVID-19 prevention with ivermectin program, which was conducted between July 2020 and December 2020 in Itajaí, Brazil. Study design, institutional review board approval, and analysis of registry data occurred after completion of the program. The program consisted of inviting the entire population of Itajaí to a medical visit to enroll in the program and to compile baseline, personal, demographic, and medical information. In the absence of contraindications, ivermectin was offered as an optional treatment to be taken for two consecutive days every 15 days at a dose of 0.2 mg/kg/day. In cases where a participating citizen of Itajaí became ill with COVID-19, they were recommended not to use ivermectin or any other medication in early outpatient treatment. Clinical outcomes of infection, hospitalization, and death were automatically reported and entered into the registry in real time. Study analysis consisted of comparing ivermectin users with non-users using cohorts of infected patients propensity score-matched by age, sex, and comorbidities. COVID-19 infection and mortality rates were analyzed with and without the use of propensity score matching (PSM). Results: Of the 223,128 citizens of Itajaí considered for the study, a total of 159,561 subjects were included in the analysis: 113,845 (71.3%) regular ivermectin users and 45,716 (23.3%) non-users. Of these, 4,311 ivermectin users were infected, among which 4,197 were from the city of Itajaí (3.7% infection rate), and 3,034 non-users (from Itajaí) were infected (6.6% infection rate), with a 44% reduction in COVID-19 infection rate (risk ratio [RR], 0.56; 95% confidence interval (95% CI), 0.53-0.58; p < 0.0001). Using PSM, two cohorts of 3,034 subjects suffering from COVID-19 infection were compared. The regular use of ivermectin led to a 68% reduction in COVID-19 mortality (25 [0.8%] versus 79 [2.6%] among ivermectin non-users; RR, 0.32; 95% CI, 0.20-0.49; p < 0.0001). When adjusted for residual variables, reduction in mortality rate was 70% (RR, 0.30; 95% CI, 0.19-0.46; p < 0.0001). There was a 56% reduction in hospitalization rate (44 versus 99 hospitalizations among ivermectin users and non-users, respectively; RR, 0.44; 95% CI, 0.31-0.63; p < 0.0001). After adjustment for residual variables, reduction in hospitalization..
Due to the well-established, long-term safety profile of ivermectin, with rare adverse effects, the absence of proven therapeutic options to prevent death caused by COVID-19, and lack of effectiveness of vaccines in real-life all-cause mortality analyses to date, we recommend that ivermectin be considered as a preventive strategy, in particular for those at a higher risk of complications from COVID-19 or at higher risk of contracting the illness, not as a substitute for COVID-19 vaccines, but as an additional tool, particularly during periods of high transmission rates. Conclusions In a citywide ivermectin program with prophylactic, optional ivermectin use for COVID-19, ivermectin was associated with significantly reduced COVID-19 infection, hospitalization, and death rates from COVID-19. Appendices Table of contents STROBE checklist Protocol modification for the calculation of infection rates Previously, we had considered the full population of Itajaí as the source for the calculation of ivermectin non-users, which falsely raised the number of non-users and, consequently, falsely reduced the infection rate among ivermectin non-users. We also excluded subjects below 18 years old and participating subjects from other cities, since their outcomes would not be accounted for in the statistics of the city of Itajaí. Figure 4 summarizes the modifications.
References
Andersson, Ottestad, Tracey, Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19?, Mol Med, doi:10.1186/s10020-020-00172-4?utm_medium=email&utm_source=transaction
Austin, An introduction to propensity score methods for reducing the effects of confounding in observational studies, Multivariate Behav Res, doi:10.1080/00273171.2011.568786?utm_medium=email&utm_source=transaction
Behera, Patro, Singh, Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: a matched case-control study, PLoS One, doi:10.1371/journal.pone.0247163?utm_medium=email&utm_source=transaction
Cairns, Giordano, Conte, Levin, Kaplan, Ivermectin promotes peripheral nerve regeneration during wound healing, ACS Omega, doi:10.1021/acsomega.8b01451?utm_medium=email&utm_source=transaction
Chen, Kubo, Ivermectin and its target molecules: shared and unique modulation mechanisms of ion channels and receptors by ivermectin, J Physiol, doi:10.1113/JP275236?utm_medium=email&utm_source=transaction
Choudhury, Das, Patra, Bhattacharya, Ghosh et al., Exploring the binding efficacy of ivermectin against the key proteins of SARS-CoV-2 pathogenesis: an in silico approach, Future Virol, doi:10.2217/fvl-2020-0342?utm_medium=email&utm_source=transaction
Ci, Li, Yu, Avermectin exerts anti-inflammatory effect by downregulating the nuclear transcription factor kappa-B and mitogen-activated protein kinase activation pathway, Fundam Clin Pharmacol, doi:10.1111/j.1472-8206.2009.00684.x?utm_medium=email&utm_source=transaction
Crump, Ivermectin: enigmatic multifaceted 'wonder' drug continues to surprise and exceed expectations, J Antibiot, doi:10.1038/ja.2017.11?utm_medium=email&utm_source=transaction
Dou, Chen, Wang, Ivermectin induces cytostatic autophagy by blocking the PAK1/Akt axis in breast cancer, Cancer Res, doi:10.1158/0008-5472.CAN-15-2887?utm_medium=email&utm_source=transaction
Heidary, Gharebaghi, Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen, J Antibiot, doi:10.1038/s41429-020-0336-z?utm_medium=email&utm_source=transaction
Hellwig, A COVID-19 prophylaxis? Lower incidence associated with prophylactic administration of ivermectin, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.106248?utm_medium=email&utm_source=transaction
Jin, Feng, Rong, The antiparasitic drug ivermectin is a novel FXR ligand that regulates metabolism, Nat Commun, doi:10.1038/ncomms2924?utm_medium=email&utm_source=transaction
Juarez, Schcolnik-Cabrera, Dueñas-Gonzalez, The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug, Am J Cancer Res
Kalfas, Visvanathan, Chan, Drago, The therapeutic potential of ivermectin for COVID-19: a systematic review of mechanisms and evidence, PREPRINT, doi:10.1101/2020.11.30.20236570?utm_medium=email&utm_source=transaction
Kaur, Shekhar, Sharma, Sarma, Prakash et al., Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes, Pharmacol Rep, doi:10.1007/s43440-020-00195-y?utm_medium=email&utm_source=transaction
Layhadi, Turner, Crossman, Fountain, ATP evokes Ca2+ responses and CXCL5 secretion via P2X4 receptor activation in human monocyte-derived macrophages, J Immunol, doi:10.4049/jimmunol.1700965?utm_medium=email&utm_source=transaction
Li, Zhao, Zhan, Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment, J Cell Physiol, doi:10.1002/jcp.30055?utm_medium=email&utm_source=transaction
Martin, Robertson, Choudhary, Ivermectin: an anthelmintic, an insecticide, and much more, Trends Parasitol, doi:10.1016/j.pt.2020.10.005?utm_medium=email&utm_source=transaction
Mastrangelo, Pezzullo, Burghgraeve, Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug, J Antimicrob Chemother, doi:10.1093/jac/dks147?utm_medium=email&utm_source=transaction
Matsuyama, Kubli, Yoshinaga, Pfeffer, Mak, An aberrant STAT pathway is central to COVID-19, Cell Death Differ, doi:10.1038/s41418-020-00633-7?utm_medium=email&utm_source=transaction
Nagai, Satomi, Abiru, Antihypertrophic effects of small molecules that maintain mitochondrial ATP levels under hypoxia, EBioMedicine, doi:10.1016/j.ebiom.2017.09.022?utm_medium=email&utm_source=transaction
Nguyen, Collins, Spence, Daurès, Devereaux et al., Double-adjustment in propensity score matching analysis: choosing a threshold for considering residual imbalance, BMC Med Res Methodol, doi:10.1186/s12874-017-0338-0?utm_medium=email&utm_source=transaction
Okeahialam, Serine protease inhibitors could be of benefit in the treatment of COVID-19 disease, Ther Adv Infect Dis, doi:10.1177/20499361211032048?utm_medium=email&utm_source=transaction
Park, Iwasaki, Type I and type III interferons -induction, signaling, evasion, and application to combat COVID-19, Cell Host Microbe, doi:10.1016/j.chom.2020.05.008?utm_medium=email&utm_source=transaction
Reis, Oliveira-Da-Silva, Tavares, Ivermectin presents effective and selective antileishmanial activity in vitro and in vivo against Leishmania infantum and is therapeutic against visceral leishmaniasis, Exp Parasitol, doi:10.1016/j.exppara.2020.108059?utm_medium=email&utm_source=transaction
Scheim, Ivermectin for COVID-19 treatment: clinical response at quasi-threshold doses via hypothesized alleviation of CD147-mediated vascular occlusion, doi:10.2139/ssrn.3636557?utm_medium=email&utm_source=transaction
Wagstaff, Sivakumaran, Heaton, Harrich, Jans, Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus, Biochem J, doi:10.1042/BJ20120150?utm_medium=email&utm_source=transaction
Wang, Gao, Dou, Chen, Li et al., Ivermectin induces PAK1-mediated cytostatic autophagy in breast cancer, Autophagy, doi:10.1080/15548627.2016.1231494?utm_medium=email&utm_source=transaction
Yan, Ci, Chen, Anti-inflammatory effects of ivermectin in mouse model of allergic asthma, Inflamm Res, doi:10.1007/s00011-011-0307-8?utm_medium=email&utm_source=transaction
Yang, Qi, Farias-Pereira, Choi, Clark et al., Permethrin and ivermectin modulate lipid metabolism in steatosis-induced HepG2 hepatocyte, Food Chem Toxicol, doi:10.1016/j.fct.2019.02.005?utm_medium=email&utm_source=transaction
Zaidi, Dehgani-Mobaraki, The mechanisms of action of Ivermectin against SARS-CoV-2: an evidencebased clinical review article, doi:10.1038/s41429-021-00430-5?utm_medium=email&utm_source=transaction
Zhang, Kim, Lonjon, Zhu, Balance diagnostics after propensity score matching, Ann Transl Med, doi:10.21037/atm.2018.12.10?utm_medium=email&utm_source=transaction
Zhang, Song, Ci, Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice, Inflamm Res, doi:10.1007/s00011-008-8007-8?utm_medium=email&utm_source=transaction
Zheng, Ma, Zhang, Xie, COVID-19 and the cardiovascular system, Nat Rev Cardiol, doi:10.1038/s41569-020-0360-5?utm_medium=email&utm_source=transaction
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit